文献速递脊柱关节炎

比美吉珠单抗治疗银屑病关节炎3年跨GRAPPA领域疗效:两项3期研究事后分析

Bimekizumab efficacy across GRAPPA domains to 3 years in patients with psoriatic arthritis: a post hoc analysis of two phase 3 studies.
PubMed 文献 · Rheumatology (Oxford) · 2026-10-10

该事后分析汇总BE OPTIMAL和BE COMPLETE两项3期研究及其开放标签扩展BE VITAL的数据,评估比美吉珠单抗160mg每4周皮下注射在活动性银屑病关节炎患者中至3年(第148周)的疗效。结果显示,在1,112例患者中,GRAPPA核心领域改善持续至3年,关节肿胀和压痛缓解率分别为59.2%和34.6%,附着点炎和指炎缓解率分别为56.6%和68.6%,皮肤和指甲银屑病清除率较高,IBD和葡萄膜炎事件罕见,炎症性心血管风险标志物改善持续。

要点

  • 比美吉珠单抗治疗3年持续改善GRAPPA核心领域。
  • 3年时关节肿胀和压痛缓解率分别为59.2%和34.6%。
  • 附着点炎和指炎缓解率分别为56.6%和68.6%。

核心结论

  • 比美吉珠单抗在银屑病关节炎患者中提供跨GRAPPA领域和全身炎症标志物的长期持续疾病控制,IBD和葡萄膜炎发生率低。

研究设计与样本

  • BE OPTIMAL(NCT03895203;生物制剂初治患者)和BE COMPLETE(NCT03896581;对TNF抑制剂应答不足/不耐受患者)两项3期研究及其开放标签扩展BE VITAL(NCT04009499)的汇总数据事后分析,评估皮下比美吉珠单抗160mg每4周一次至3年(第148周)。

主要发现

  • 在1,112例接受比美吉珠单抗治疗的患者中,GRAPPA核心领域改善持续至3年。
  • 3年时肿胀关节计数和压痛关节计数缓解率分别为59.2%和34.6%,54.8%的患者达到ACR应答标准≥50%改善(改良无应答者填补[mNRI])。
  • 附着点炎(LEI=0)和指炎(LDI=0)缓解率分别为56.6%(mNRI)和68.6%(NRI)。
  • 高比例患者达到皮肤和指甲银屑病清除(PASI100:64.6%;mNAPSI=0:68.0%;mNRI)。
  • IBD和葡萄膜炎事件罕见,炎症性心血管风险标志物改善持续。

临床怎么用

  • 比美吉珠单抗可作为银屑病关节炎长期治疗选择,支持其用于异质性表现。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: To evaluate the long-term efficacy of bimekizumab in patients with psoriatic arthritis (PsA) across the Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA) domains, PsA-related conditions, and comorbidities. METHODS: Post hoc analysis of pooled data from BE OPTIMAL (NCT03895203; biologic-naïve patients) and BE COMPLETE (NCT03896581; patients with prior inadequate response/intolerance to tumour necrosis factor inhibitors) phase 3 studies, and their open-label extension BE VITAL (NCT04009499), which assessed subcutaneous bimekizumab 160 mg every 4 weeks in patients with active PsA. Efficacy was assessed to 3 years (Week 148) across GRAPPA core domains, PsA-related conditions (inflammatory bowel disease [IBD] and uveitis), and inflammatory markers of cardiovascular risk. RESULTS: Among 1,112 bimekizumab-treated patients with PsA, improvements were sustained across the GRAPPA core domains to 3 years. Resolution of swollen and tender joint count at 3 years was achieved by 59.2% and 34.6% of patients, respectively, while 54.8% achieved ≥50% improvement from baseline in American College of Rheumatology response criteria (modified non-responder imputation [mNRI]). Enthesitis (LEI=0) and dactylitis (LDI=0) resolution was also achieved by 56.6% (mNRI) and 68.6% (NRI) of patients, respectively. A high proportion of patients achieved skin and nail psoriasis clearance (PASI100: 64.6%; mNAPSI=0: 68.0%; mNRI). IBD and uveitis events were rare, and inflammatory cardiovascular risk marker improvements were sustained. CONCLUSION: Bimekizumab provided long-term, sustained disease control across GRAPPA domains and systemic inflammation markers in patients with PsA, with low rates of IBD and uveitis, supporting its use as a long-term treatment for the heterogeneous manifestations of PsA. CLINICAL TRIAL REGISTRATION: BE OPTIMAL: NCT03895203; BE COMPLETE: NCT03896581; BE VITAL: NCT04009499.

来源:Rheumatology (Oxford),查看原文。版权归原作者所有。

引用

  1. Deodhar A, Gottlieb AB, Merola JF, et al. Bimekizumab efficacy across GRAPPA domains to 3 years in patients with psoriatic arthritis: a post hoc analysis of two phase 3 studies. Rheumatology (Oxford). 2026. PMID: 42860055. doi:10.1093/rheumatology/keag557

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。